FDA Desk — Oct 16, 2026: Ten Active Recalls, Zero Class I, Sterility Failures Dominate

No Class I recalls were posted in today's batch; the risk profile skews toward Class II quality and sterility deficiencies across topical, ophthalmic, and oral Rx products. Four items involve sterility assurance or microbial contamination findings, three reflect dissolution or stability failures, two involve packaging/temperature handling defects, and one Amazon-branded acetaminophen lot remains unclassified pending FDA review.

Companion lots from the same Canadian contract manufacturer — both tied to a single contamination root cause under limited IL distribution. Pharmacies holding Rugby-labeled stock should check lot numbers immediately.

Sterility-assurance failures on ophthalmic products carry elevated infection risk given direct ocular exposure; both recalls warrant prompt shelf removal.

Crystallization in an injectable opioid product poses dosing-accuracy and particulate-injection risk; six affected lots span expiration dates through mid-2027.

A single lot (YN0099) affected; prescribers administering this oncology implant should confirm cold-chain integrity before use.

Pending FDA classification; discoloration complaints often precede stability or impurity findings and may be upgraded once root-cause analysis concludes.